Literature DB >> 1910055

Primary anetoderma associated with a wide spectrum of autoimmune abnormalities.

E Hodak1, O Shamai-Lubovitz, M David, B Hazaz, M Lahav, M Sandbank.   

Abstract

Although the underlying pathologic mechanisms of primary anetoderma have not yet been identified, data suggest the participation of an immunologic mechanism in some cases. In a woman with clinical and histopathologic features of primary anetoderma (Jadassohn-Pellizzari type) of 30 years' duration, laboratory investigation disclosed positive antinuclear factor, hypocomplementemia, hypergammaglobulinemia, granular deposits of immunoreactants along the dermoepidermal junction, and fibrillar deposits in the papillary dermis. In addition, she was found to have autoimmune hemolysis and circulating lupus anticoagulant associated with recurrent deep-vein thrombosis and a history of Graves' disease (starting 5 years after onset of primary anetoderma). To our knowledge, none of the latter three autoimmune conditions has been previously associated with primary anetoderma.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1910055     DOI: 10.1016/0190-9622(91)70218-q

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  3 in total

Review 1.  Primary anetoderma and antiphospholipid antibodies--review of the literature.

Authors:  Emmilia Hodak; Michael David
Journal:  Clin Rev Allergy Immunol       Date:  2007-04       Impact factor: 8.667

2.  Eruptive anetoderma in a patient with systemic lupus erythematosus.

Authors:  Nam-Ji Jeong; Seung-Bae Park; Myung Im; Young-Joon Seo; Jeung-Hoon Lee; Young Lee
Journal:  Ann Dermatol       Date:  2014-09-26       Impact factor: 1.444

3.  A Clinicoimmunohistopathologic Study of Anetoderma: Is Protruding Type More Advanced in Stage Than Indented Type?

Authors:  Jung Eun Kim; Ki Min Sohn; Young Jun Woo; Kwan Ho Jeong; Miri Kim; Jeong Deuk Lee; Jun Young Lee; Hyun Jeong Park; Gyong Moon Kim; Chul Jong Park; Dong Soo Yu; Hoon Kang
Journal:  J Immunol Res       Date:  2016-12-28       Impact factor: 4.818

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.